NAs
NAs is a pharmaceutical drug with 8 clinical trials. Currently 6 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
6
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B)
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)
Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
Clinical Trials (8)
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B)
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)
Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis
Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients
Nursing Activity Score (Nursing Activities Score-NAS) Verification of Turkish Version
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8